Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 3/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL725995 | 0.98 | TYMP (0.46) | TYMPFGFR1SLC22A6HPRT1POLB | |
| SCHEMBL725994 | 0.87 | POLB (0.38) | TYMPFGFR1SLC22A6POLBHSD17B10 | |
| SCHEMBL2698042 | 0.84 | CTSK (0.38) | TYMPFGFR1SLC22A6POLBHSD17B10 | |
| SCHEMBL727586 | 0.79 | TYMP (0.67) | TYMPFGFR1SLC22A6HPRT1 | |
| SCHEMBL726337 | 0.78 | TYMP (0.37) | TYMPFGFR1SLC22A6ALDH1A1LMNA | |
| SCHEMBL2698038 | 0.77 | P2RY14 (0.34) | TYMPPOLBHSD17B10ALDH1A1LMNA | |
| SCHEMBL2698051 | 0.77 | P2RY14 (0.34) | TYMPPOLBHSD17B10ALDH1A1LMNA | |
| SCHEMBL2694574 | 0.77 | FGFR1 (0.65) | TYMPFGFR1SLC22A6HPRT1POLB | |
| SCHEMBL727588 | 0.77 | TYMP (0.67) | TYMPFGFR1SLC22A6HPRT1 | |
| SCHEMBL2694580 | 0.74 | FGFR1 (0.65) | TYMPFGFR1SLC22A6HPRT1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4745329-B2 | — | — | 2011-08-10 | — | — | JP | claimed |
| JP-2007526048-A | — | — | 2007-09-13 | — | — | JP | claimed |
| US-20070185062-A1 | Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2007-08-09 | — | — | US | claimed |
| EP-1750572-A2 | METHOD OF DETERMINING THE SYMPATHETIC TONE AND SYSTEM FOR MEASUREMENT THEREOF | Stressmeter A/S (DK) | 2007-02-14 | — | — | EP | claimed |
| WO-2005084529-A2 | METHOD OF DETERMINING THE SYMPATHETIC TONE AND SYSTEM FOR MEASUREMENT THEREOF | STRESSMETER A/S (DK) | 2005-09-15 | — | — | WO | claimed |
| US-9522932-B2 | Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2016-12-20 | — | — | US | disclosed |
| US-9249177-B2 | Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2016-02-02 | — | — | US | disclosed |
| US-20160009750-A1 | PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2016-01-14 | — | — | US | disclosed |
| EP-1720890-B1 | PHOSPONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | LEUVEN K U RES & DEV (BE) | 2015-05-20 | — | — | EP | disclosed |
| US-20140316127-A1 | PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2014-10-23 | — | — | US | disclosed |
| US-8809520-B2 | Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2014-08-19 | — | — | US | disclosed |
| US-20140039179-A1 | PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2014-02-06 | — | — | US | disclosed |
| US-8501709-B2 | Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) | 2013-08-06 | — | — | US | disclosed |
| US-20120108531-A1 | PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) | 2012-05-03 | — | — | US | disclosed |
| US-8076310-B2 | Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) | 2011-12-13 | — | — | US | disclosed |
| US-20070185062-A1 | Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2007-08-09 | — | — | US | disclosed |
| EP-1750572-A2 | METHOD OF DETERMINING THE SYMPATHETIC TONE AND SYSTEM FOR MEASUREMENT THEREOF | Stressmeter A/S (DK) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005084529-A2 | METHOD OF DETERMINING THE SYMPATHETIC TONE AND SYSTEM FOR MEASUREMENT THEREOF | STRESSMETER A/S (DK) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140039179-A1 | PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | PNP, NUDT1, TYMP | TYMP 3/4885FGFR1 1742/4885SLC22A6 1224/4885 |
| US-20120108531-A1 | PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | TYMP, PNP, NUDT1 | TYMP 1/4885FGFR1 946/4885SLC22A6 3113/4885 |
| US-20070185062-A1 | Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | ENTPD5, PPA1, TYMP | TYMP 3/4885FGFR1 1128/4885SLC22A6 1213/4885 |
| US-20160009750-A1 | PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | PNP, NUDT1, TYMP | TYMP 3/4885FGFR1 1742/4885SLC22A6 1224/4885 |
| US-20140316127-A1 | PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | PNP, NUDT1, TYMP | TYMP 3/4885FGFR1 1742/4885SLC22A6 1224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.